Pharmaceutical value under uncertainty: a theory of reproducible therapeutic surplus

Pharmacoeconomics has achieved considerable influence by providing formal tools for comparing pharmaceutical interventions in terms of costs and consequences. Its most established instruments, especially cost-effectiveness analysis and related evaluative frameworks, have supplied health systems with a disciplined language for priority setting, reimbursement appraisal and resource allocation (1,2). This contribution is substantial and should not be understated. Yet the intellectual success of conventional pharmacoeconomics has also encouraged a narrowing of its theoretical horizon. In much of its dominant form, pharmaceutical value is treated as if it could be adequately represented through a relatively static relation between present expenditure and measurable health gain.That reduction has analytical advantages, but it also entails a substantial loss of theoretical depth. Pharmaceutical interventions do not enter empty calculative space. They are introduced into health systems characterised by imperfect information, asymmetries of institutional power, intertemporal trade-offs, administrative delay, evidential incompleteness and politically mediated thresholds of acceptability. Even where the formal apparatus of economic evaluation is technically rigorous, the broader process by which value is formed, recognised and acted upon remains only partially captured by standard efficiency metrics. In this sense, conventional pharmacoeconomics is not wrong so much as incomplete. It explains an important part of the problem, but not the full architecture within which pharmaceutical value is generated and judged. This incompleteness becomes particularly evident once one distinguishes between the evaluation of a medicine as an isolated intervention and the evaluation of a medicine as an element within a reproducing institutional system. A pharmaceutical technology may satisfy conventional criteria of efficiency while simultaneously imposing strains on future therapeutic organisation, reimbursement flexibility, supply resilience or distributive legitimacy. By the same token, a therapy that appears expensive in the short run may contribute to the strengthening of long-term therapeutic capacity by reducing downstream fragility, preserving clinical options or stabilising patterns of care. The prevailing analytical vocabulary of pharmacoeconomics has struggled to articulate these broader dynamics in a systematic way.The reduction of pharmaceutical value to static efficiency is increasingly difficult to defend. Even within mainstream health economics, important work has acknowledged that cost-effectiveness analysis, although indispensable, does not exhaust the evaluative terrain of health policy (3,4). Health technology assessment bodies routinely consider matters that exceed the simple ratio between cost and effect, including severity, uncertainty, unmet need, feasibility of implementation, budgetary sustainability and wider social or institutional concerns. The real decision space is therefore already broader than the formal language by which it is often represented. Moreover, pharmaceutical decision-making unfolds under conditions of uncertainty that are not merely technical but structural. Evidence at the point of pricing and reimbursement is frequently incomplete, immature or contingent upon evolving real-world use. Uncertainty concerns not only parameter values in a model, but the stability of treatment effects over time, the generalisability of trial results, the behaviour of providers and patients, the durability of supply, and the institutional willingness to sustain funding commitments. For this reason, uncertainty is not an external nuisance appended to otherwise stable valuations; it is internal to the constitution of value itself (5)(6)(7).A further limitation of static efficiency lies in its weak grasp of temporality. Static assessment is primarily concerned with whether a given intervention appears worthwhile at the moment of appraisal. Yet pharmaceutical systems are not static allocation devices. They are historically layered, institutionally constrained and continuously reproducing arrangements that must preserve future therapeutic possibility while managing present scarcity. Recent work on dynamic efficiency has this point by that may the conditions to sustain and therapeutic the same It also to the capacity of health systems to preserve therapeutic resilience and value is only as is the of whether present pharmaceutical or the future conditions of care. A health may interventions that are within while in distributive or it may or interventions contribution lies in to therapeutic under Static efficiency is therefore a but It a of but not its full and institutional a theoretical to that Its is that pharmaceutical value should be not only in relation to health and present but also in relation to the capacity of a pharmaceutical intervention to or the future therapeutic of the health system. the the of therapeutic The to the generated a pharmaceutical intervention present therapeutic while also the institutional and conditions under which future therapeutic to be contribution is the a of standard by that its dominant evaluative in the of uncertainty, institutional and intertemporal it an through which pharmaceutical value may be as an institutionally mediated and than as a merely static efficiency This does not economic it to economic evaluation within a of therapeutic value is politically and historically broader of the is to the theoretical of pharmacoeconomics by it into with institutional and of pharmaceutical systems are only by in the the conditions that therapeutic A must therefore not only whether a medicine is but whether it to the of therapeutic capacity under conditions of uncertainty, and institutional It is this that the present analysis has the most analytical language of pharmacoeconomics it a disciplined to therapeutic under resource Its lies in its costs are related to are and are given a for reimbursement and In this the of cost-effectiveness is within the of cost-effectiveness should not be with theoretical analysis does not value in its it one of it under a of It whether a pharmaceutical intervention to but it does not by itself whether that intervention is institutionally politically or with the of therapeutic Even with technical the remains a of a broader evaluative This limitation is not merely reimbursement systems do not on They through decision in which unmet need, severity, social value and institutional feasibility or into The of cost-effectiveness therefore with the that decision it as a The formal remains but the of value the is not that cost-effectiveness analysis should be but that it should be as pharmacoeconomics it as the of pharmaceutical it to the between evaluative and institutional is not It the that pharmaceutical value is by a of that be to a efficiency ratio of standard under conditions of In economic evaluation already uncertainty and has increasingly for including analysis, analysis, and tools are indispensable, but often most where uncertainty is and to formal frequently of uncertainty that are only partially to the point of may be on or on be in Uncertainty may not only the of effect, but the stability of the evidential on which the intervention has In the is whether a is to It is whether the of is for efficiency to the upon This is uncertainty in pharmaceutical policy is not merely it is also and in for evidential fragility, and that is by unmet and the to work on reimbursement has that uncertainty is not in a or but through and the decision is therefore not uncertainty but uncertainty through institutional this is the of standard becomes A on cost and value as than it It may also the between present and future are not in They are institutional under often with that are politically and difficult to A of pharmaceutical value that does not this of uncertainty remains value is in a It is mediated by that appraisal and evaluative into funding For this reason, the same pharmaceutical technology reimbursement not only of or but the institutional of assessment in and matters assessment is not a of It is an process of and which are which are which are and which be In do not pharmaceutical in its This is particularly evident where pricing and reimbursement are In the value to a medicine the between appraisal and budgetary than technical Evidence the for that economic evaluation does influence pricing but within a in which broader value criteria only and a is value is institutionally pharmacoeconomics with a of in which merely external to the and of that They also whether pharmaceutical or the broader of care. appears as a intervention at the of isolated may once through the institutional conditions for and long-term therapeutic has often treated these institutional as the real analytical The present the is not to pharmaceutical it is of that this to are or systems that in formal the same The of conventional pharmacoeconomics therefore not only in its treatment of efficiency and uncertainty, but also in its of the institutional through which value is pharmaceutical reimbursement is as an institutional process than as a merely technical of economic it becomes that value is by and as much as by formal bodies do not cost-effectiveness They under evidential the and of delay, the of and economic within broader severity, unmet need, and Pharmaceutical in is therefore not merely It is institutionally becomes especially enter the with immature conventional appraisal often to or within this space of institutional is not to but to a through which uncertainty, and budgetary be for a politically and decision to be In this sense, pharmaceutical under real-world value is frequently treated as contingent and than as a stable at the moment of this The of including and that have policy where is incomplete, are and institutional is substantial therefore be by technical in pricing or reimbursement It also a wider in the of uncertainty is treated as an nuisance but as a of pharmaceutical appraisal that must itself be this particularly often evidential and In have not merely as have through which the between and is the formal appraisal into downstream and This may but it may also administrative and evidential that the of reimbursement and while at the same the to funding and whether the interventions in this value for and health systems is therefore the of reimbursement but also the of static to the broader may funding in does not only in clinical or It is also by in appraisal institutional and the of uncertainty Pharmaceutical value is mediated through institutional of as an a or a of is It is in the of the decision broader of pharmaceutical value a in the of Static the medicine as an isolated of appraisal. A the that enter institutional that must continuously capacity to therapeutic is at is not only whether a pharmaceutical intervention appears worthwhile at a given but whether the terms of its preserve or the future of of pharmaceutical systems strengthening is particularly it pharmaceutical in relation to the and to and to and related this a medicine does not value in a Its real contribution on the resilience of the of the capacity for and the of treatment and the possibility of the health system. are not external They are part of the conditions under which therapeutic value is becomes particularly in pharmaceutical the of an as A may a to the and an reduction in simultaneously its to supply and supply or may a expenditure while preserving the capacity to treatment The therapeutic of the medicine is the institutional capacity to its The economic for supply on whether the health and resource of the and its Evidence the of treatment although the economic of arrangements remains therapeutic a analytical for the through which a medicine is same point be A pharmaceutical intervention may value it the and capacity of the This matters the value of pharmaceutical Evidence on that in supply and in pharmaceutical are with treatment and broader that are captured by A medicine may therefore in an while real value once its on of and is In conventional appraisal as becomes into which it is value may not be in static economic it concerns not only present but the of future therapeutic This is one pharmaceutical value should be to than to influence future for future resilience and the sustainability of therapeutic this and is value appears as a static relation between cost and and as a dynamic relation between present intervention and future therapeutic value is within institutional the between efficiency and value becomes A pharmaceutical intervention may within the of a conventional appraisal and once broader and distributive are This is not an It is a possibility within health systems that must present future is that evaluative often of into a dominant Yet work on decision analysis has that health technology assessment increasingly value that conventional including and wider Even where is not its analytical remains value in decision-making is and institutionally A that it to efficiency that as of or policy is that the architecture to uncertainty may itself and preserve under uncertainty, but also and evidential into future administrative This is evident one for which to with therapeutic that conventional reimbursement arrangements are often on to a stable between and especially in of and in does not is that decision that funding are mediated by institutional of reimbursement and appraisal that may of in evidential social value and the of concerns This that value be with the of a the institutional in which the is appears under one decision architecture may be as or under the broader that policy to with uncertainty may over not as but as on administrative evidential and the broader for and that does not into or value once are into The between efficiency and value is therefore not It is in the institutional of reimbursement these pharmaceutical value be adequately represented as the of matters is not only whether a medicine appears but whether its future with and to the of therapeutic these conditions are static efficiency remains but only as one moment within a and of The of therapeutic is introduced to a of pharmaceutical value that is not adequately captured by standard static In conventional value is represented as the relation between costs and health at a given decision Even broader value are are often appended to the as than treated as of the process has increasingly recognised this the of value to health and the of into evaluative therapeutic is as the a pharmaceutical intervention present therapeutic while also stabilising or the future capacity of the health to further therapeutic The of is It not merely to as but to that clinical it to the of the therapeutic system. The is therefore dynamic and It does not in the in the appraisal model, but in the between uncertainty, institutional and it the that pharmaceutical value be to health of it the that broader value be captured by a of further to an otherwise static The on value including value and not represented in cost-effectiveness analysis, is important it that conventional value are incomplete. the same time, that also the of the value is often by than as a and institutionally mediated process of therapeutic therapeutic arrangements or institutional Its analytical present pharmaceutical the conditions under which therapeutic be economic reimbursement and clinical institutional of this the allocation of under uncertainty, with that may the decision horizon. The is whether or future therapeutic capacity once the costs of have therapeutic a for these that or be Its is its remains contingent upon the institutional of the to be it must be therapeutic may be as at therapeutic uncertainty and future therapeutic remains in the if a pharmaceutical intervention does not present The does not conventional it it as a but This is important broader value have the of value so that its analytical becomes is uncertainty Pharmaceutical value under uncertainty is not by it also on uncertainty is and intervention that in clinical terms but uncertainty, evidential or institutional may a than one that and therapeutic The on the in health technology assessment is it that have to The present to a therapeutic is not isolated value element It is a Its is to pharmaceutical interventions may value than static the future of therapeutic capacity under conditions of uncertainty and institutional In this sense, the the analytical the of at one moment in to the of therapeutic possibility value but also that the remains and often to into decision is A therapy to therapeutic its is with the or strengthening of the arrangements for care. This resilience of supply, of administrative feasibility and into The of pharmaceutical systems strengthening is it as upon and that sustain and over resilience the same point by that health systems must be not only in terms of static but also in terms of capacity to and under is future A pharmaceutical intervention may value by preserving the or to future future of therapy or future This is where the on value becomes especially in this has the and the of value into formal appraisal. and of value and for real value in particularly where or matters should not be treated as lies in may only resilience present therapeutic therapeutic institutional capacity to may merely therapeutic therefore on the of present uncertainty, and future therapeutic of therapeutic becomes with conventional health metrics. as or are to and the generated by is evaluation Yet these achieved or health do by whether the through which that is or the future capacity of the to is not a of health as It is a of A may in and of but it does not whether that through a reimbursement that future fragility, future options or on a therapy may value not in health it therapeutic or under of have that value is in the than in standard and that in and it be The value generated uncertainty, and future in a This is the of the value is where present therapeutic also the future capacity of the to value appraisal these that therapeutic should be not as an isolated value but as a and of pharmaceutical A of value must by the that value is through technical Pharmaceutical value is not a to be with It is and within institutional that uncertainty, and of analysis remains important within this but it does not as a It through and its on decision systems or This has value must be as mediated than The same therapeutic technology may not its has but institutional arrangements in treatment of uncertainty, of of and of work on health technology assessment has this that is not only by formal but by institutional social and decision work has further that where criteria are often remains and with important for and value must be as than merely A medicine does not enter a decision it a health that must to therapeutic The is therefore not only whether the intervention appears at the moment of but whether its or the capacity of the to therapeutic In this sense, pharmaceutical value is as institutionally mediated therapeutic The of value is not the by the but the to which that is in and with the of therapeutic matters it as a reimbursement A decision is not merely it an intervention with It is it present therapeutic in a that remains with future future treatment and the of care. this is pharmacoeconomics a of a of institutionally therapeutic value is must be therapeutic does not health cost in an It present therapeutic are generated in a that or the future capacity of the health to further This is dynamic it unfolds time, and it is contingent it on present social between and health systems under conditions of health work on allocation is of pricing over the have that conventional cost-effectiveness may pricing once future or and the of value are and work on the of pharmaceutical value has that the allocation of value between and health systems is not a but to the between static and dynamic efficiency This is for the present therapeutic not only on whether value is but on whether it is in a that future therapeutic than under uncertainty also to that standard appraisal often efficiency may the present effects while or future institutional uncertainty or downstream Yet the value of may once one whether the decision for uncertainty in a and the into patterns of expenditure or that therapeutic In this the by and is cost-effectiveness and dynamic efficiency be to and the relation between theoretical treatment of dynamic therefore a It explains interventions may and interventions with may substantial future if preserve value or therapeutic Uncertainty is to this process it conditions whether present are or A of pharmaceutical value that uncertainty in its with of value is if it as a than as an internal of Pharmaceutical value is therapeutic is technically but is or on supply is not external to It is one of the conditions under which value becomes and This is must be not merely as the of but as part of value that be is not comparing pharmaceutical policy and have that appraisal systems not only in formal but in the is into conditions A medicine may through formal evaluative thresholds and to stable therapeutic if reimbursement systems or institutional are weak to sustain its the at this A pharmaceutical is not one that It is one that uncertainty, of and therapeutic The resilience on health systems and pharmaceutical supply that of on institutional and especially under work on pharmaceutical supply that and be and In a on therapeutic resilience is therefore not an systems It is a of This also the distributive of the The is not only whether value but under and with of A pharmaceutical intervention that for a of under institutional arrangements may therapeutic than one present is but and are much must therefore be not only by but by a real therapeutic system. these a of is institutionally mediated than It is generated than it is and resilience these whether therapeutic be over therapeutic is the given to that broader of It does not conventional but it it within a and these value as a institutionally mediated and than as the static of a efficiency pharmaceutical value is through the of therapeutic health technology assessment to the static of present costs and present but are The is that should be the of efficiency a broader assessment of whether present or the future capacity of the health to therapeutic This a as much as a work on is particularly it as a process in which not only on but also on and The by and that conventional value often for the and of while the this into for bodies are with the present value is institutionally mediated and the of not only on but also on whether the architecture is to in of uncertainty, distributive and same is by work on within A systematic of has that are by that are not captured in formal frameworks, including and are not merely They are part of the conditions under which value is and into A on therapeutic does not but it does It a for therapeutic resilience and future as of appraisal than as concerns the formal does not that should cost the cost remains value that with health but of value is on this broader are only if disciplined by the of and the of The present therefore does not an of It for a in which health uncertainty and future therapeutic possibility are within a that cost as a the is assessment should static efficiency of value economic but it within a broader architecture of institutional resilience and temporality. This is a but not a of It is a that the under evaluation has than the to concerns pricing and value is generated and institutionally pricing be treated as a technical of willingness to for health the of and therefore influence whether therapeutic value remains at the of the health that appears under may therapeutic if it flexibility, or a of the value by the point has as and increasingly the and have that the between and should be as a than as a of institutional analysis the of real-world and between and bodies as into broader A of therapeutic this and reimbursement should not be the that value is at They should be to evidential while preserving institutional and therapeutic also on and that to not merely but bodies and on and between pricing and uncertainty analysis with the present uncertainty is reimbursement should be not as a of a value but as a to and future In this sense, pricing should not in a static sense, but in a dynamic intertemporal of reimbursement especially therapeutic expenditure is at the of a treatment while its over a therapy for this reimbursement an at treatment and a part of the to The intervention and its therapeutic but the of evidential and between and A may preserve for future where treatment durability remains that and do not the clinical already the of systematic long-term for this therapy The economic concerns whether the therapeutic to with the capacity to care. This is not to It the of the of and the of therapeutic the institutional allocation of to the of pharmaceutical is also a distributive value is by reimbursement should to whether the conditions are and work on reimbursement has that are by formal including unmet need, clinical budgetary and institutional This that reimbursement already and often that value is and The contribution of the present is to that pricing and reimbursement should not only to present but to preserve the future conditions under which value to be and concerns and policy uncertainty is than should not be merely as to difficult They should be as institutional for the to value on whether uncertainty in a preserve where and than the of therapeutic on and appraisal is and have that analysis the and of by values and the present that has policy and related policy should not be only by whether They should also be in terms of preserve and the future of therapeutic that policy should A policy at under uncertainty, evidential through real-world and to or funding an is with the that appraisal must a decision and as patterns and It also the that for broader policy is that should not merely to be in it but in it value over A on therapeutic that present while reimbursement on the of future therapeutic This that with pricing with and with It also the for uncertainty and In this the future of may on static than on of value as a dynamic and these that should be not merely as a for but as an institutional technology for the long-term of therapeutic in this has theoretical it that value should be as the static of efficiency analysis The conventional remains but it becomes once value is as uncertainty, through institutional and only within systems of therapeutic The of therapeutic therefore pharmaceutical value as institutionally mediated and than merely the to the relation between assessment and appraisal. Recent work in the has that the between the should be treated as a especially in the of where assessment and appraisal increasingly the present therapeutic is not to the assessment of clinical and economic its on is within institutional The therefore the of assessment while that value is only through appraisal. In this sense, it a between technical and institutional the the of efficiency in to therapeutic under This is a substantial It that the evaluative is not only whether a medicine is funding but whether its of the future capacity of the health to a pharmacoeconomics into with with work as a process for or over The is not the of the decision and value within a institutional and evidential the theoretical pharmaceutical value is and by implementation, and institutional standard are often to the real of This does not that cost-effectiveness analysis should be It that it should be within broader evaluative of evolving and work is A that is of within economic a of tools is to This is with the present therapeutic is to be captured through one or one It is to conventional economic evaluation with assessment where dynamic or same point to The not only but also for and to decision contribution is important it that assessment be than merely the present this that evaluation should and value are are and should be further concerns and A of economic evaluation and that and are represented in with important in for in this matters therapeutic be if value is treated as of whether is or should therefore do than as a They should whether therapeutic is the and is a for broader of dynamic systems in Recent work has that often to the of long-term and that dynamics in real health systems This does not that appraisal dynamics It does that pharmacoeconomics should be to of policy and especially where therapeutic value on than on clinical by this is The is therapeutic has as a theoretical to of value that are treated work should its where it with broader and where it than merely is analytical The to be through that whether its be in real assessment one for this it decision-making under evolving